Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir
Beyond Truvada – what is the future of PrEP?
Bictegravir matches dolutegravir in first-line treatment
Two-drug protease inhibitor treatment as effective as three-drug treatment – and fewer stop due to side-effects
First large HIV prevention trial using antibodies will probably not be the last
The Miami monkey cured with two antibodies
The long tail of injectable PrEP is especially long for women
Drug resistance accumulates fast in people with low but detectable viral loads, Kenyan study finds
Studies confirm long-term effectiveness of new single-tablet regimens
